Gapping up
In reaction to earnings/guidance:
- SKIL +5.5%, LLY +5.1% (guidance update), COHU +1.5% (updated mid-term financial target models), BCO +0.8%
Other news:
- CCMP +19.8% (Entegris and CMC Materials (CCMP) announce a definitive merger agreement under which Entegris will acquire CMC Materials in a cash and stock transaction with an enterprise value of ~$6.5 bln)
- OCGN +5.8% (reports new data suggest COVAXIN (BBV152) vaccine candidate generates robust immune memory to COVID-19 and variants of concern for at least six months after vaccination)
- LLY +5.1% (mirikizumab met primary endpoint and all key secondary endpoints in Phase 3 study)
- DWAC +4.4% (enters into technology and cloud services agreement with Rumble)
- VIR +4.3% (preclinical data highlight the significant antigenic shift of the Omicron variant)
- CONN +3.3% (authorization of $150 million share repurchase program)
- NILE +3.3% (authorized a stock repurchase program under which BitNile may repurchase up to $50 million of its outstanding common stock over a three-year period commencing December 15)
- REE +2.7% (forms strategic agreement with Hitachi America to accelerate the adoption of EVs)
- PANL +2.7% (announces the passing of CEO and founder Ed Coll)
- ONEW +2.7% (entered into a definitive agreement to acquire a majority interest in Quality Boats )
- INCY +2% (FDA accepts for Priority Review of sNDA for ruxolitinib for treatment of vitiligo)
- BLU +2% (prices offering of 25 mln shares of common stock at $8.00 per share)
- CAN +2% (secured purchase order of 30000 Bitcoin mining machines)
- XXII +1.8% (ACB and XXII announce IP license agreement with CRON)
- KBR +1.3% (awarded eight prime contracts on GSA's ASTRO program)
- LAZR +1.2% (priced upsized offering of $550.0 mln (from $500 mln) of its 1.25% convertible senior notes due 2026 with net proceeds ~$535.3 mln)
- CMI +1.1% (authorizes share repurchase up to $2 bln in shares of common stock upon completion of its 2019 $2 bln share repurchase program)
- TTC +1% (increases dividend)
- AVIR +1% (introduces updated program for AT-527 in COVID-19; to close out Phase 3 MORNINGSKY trial)
- KULR +1% (received three-year multi-million dollar deployment order for its Passive Propagation Resistant solution suite from Volta Energy Products a subsidiary of Viridi Parente)
Analyst comments:
- FATE +4.7% (upgraded to Outperform from Neutral at Wedbush)
- HUN +2.5% (upgraded to Buy from Neutral at Goldman)
- IRTC +2.5% (upgraded to Buy from Neutral at Citigroup)
- BKNG +2.4% (upgraded to Overweight from Neutral at JP Morgan)
- IIVI +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CMP +1.9% (upgraded to Neutral from Sell at Goldman)
- KEY +1.8% (upgraded to Buy from Underperform at BofA Securities)
- MAS +1.6% (upgraded to Overweight from Equal Weight at Barclays)
- CMA +1.2% (upgraded to Neutral from Underweight at JP Morgan)
- EW +1.2% (upgraded to Buy from Neutral at Citigroup)
- EDR +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)